References

Data on file. Eagle Pharmaceuticals, Inc.
Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381-387.
Brandom BW, Kang A, Sivak EL, Young MC. Update on dantrolene in the treatment of anesthetic induced malignant hyperthermia. SOJ Anesthesiol Pain Manag. 2015;2(2):1-6.
Schütte JK, Becker S, Burmester S, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs. Eur J Anaesthesiol. 2011;28(4):256-264.
Dantrium Intravenous [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies, Inc.; 2014.
Revonto [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2014.
RYANODEX [prescribing information]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2017.
Managing an MH crisis. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/healthcare-professionals/managing-a-crisis. Accessed March 24, 2017.
Revonto Dosage and Administration. Revonto website. http://revonto.com/dosage.asp. Accessed June 4, 2018.
Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant Hyperthermia Susceptibility. 2003 [updated 2013]. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 2014;118(2):369-374.
Rosenberg H. Current state of malignant hyperthermia and the use of Dantrium IV as treatment. Anesthesiology News. 2010:20-21.
Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498-507.
Brandom BW. Cases from the North American MH Registry/MHAUS [1992 through 2012].
Post acute phase. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/healthcare-professionals/after-a-crisis/post-acute-phase. Accessed March 24, 2017.
Pollock NA, Machon RG, Rosenberg H. Early development, identification of mode of action, and use of dantrolene sodium. The role of Keith Ellis, Ph.D. Anesthesiology. 2017;126(5):774-779.
FAQs: Stocking an MH cart. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/faqs/stocking-an-mh-cart. Accessed May 5, 2017.

Important Safety Information

RYANODEX® is not a substitute for appropriate supportive measures in the treatment of malignant hyperthermia (MH), including discontinuing use of MH-triggering anesthetic agents, managing the metabolic acidosis, instituting cooling when necessary, and administering diuretics to prevent late kidney injury due to myoglobinuria (the amount of mannitol in RYANODEX® is insufficient to maintain diuresis).

RYANODEX® is associated with skeletal muscle weakness such as loss of grip strength and weakness in the legs, as well as drowsiness, dizziness, dysphagia, dyspnea, and decreased inspiratory capacity. Patients should not be permitted to ambulate without assistance until they have normal strength and balance. Care must be taken to prevent extravasation of RYANODEX® into the surrounding tissue due to the high pH of the reconstituted RYANODEX® suspension and potential for tissue necrosis.

Please see full Prescribing Information.

Indication

RYANODEX® (dantrolene sodium) for injectable suspension is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.

Indication and Important Safety Information

VIEW ALL